Galantamine

Download image
Mode of action
Galantamine
Transporter zone
No interaction
Enzyme zone
Acetylcholinesterase
Butyrylcholinesterase
Receptor zone
Important for clinical effects
Ion channel zone
No interaction
References
  1. Bond M, Rogers G, Peters J, et al. (2012) The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 16: 1-470.
  2. Deardorff WJ, Feen E and Grossberg GT. (2015) The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease. Drugs Aging 32: 537-547.
  3. Samochocki M, Hoffle A, Fehrenbacher A, et al. (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305: 1024-1036.

For more detailed explanation of the principles of the VM Library

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind